Maximum Atomoxetine Dosing
The maximum prescribed dose of atomoxetine is 100 mg/day in adults and 1.4 mg/kg/day (or 100 mg/day, whichever is less) in children and adolescents, though some guidelines permit up to 120 mg/day in specific populations.
Dosing by Population
Children and Adolescents (≥6 years, <70 kg)
- Target dose: 1.2 mg/kg/day 1
- Maximum dose: 1.4 mg/kg/day 2 or 100 mg/day, whichever is less 2
- Start at 0.5 mg/kg/day for one week, then increase to target 1
- Can be given once daily in the morning or divided into two doses (morning and late afternoon/early evening) 1
Children and Adolescents (≥6 years, ≥70 kg) and Adults
- Starting dose: 40 mg/day 1
- Target dose: 80 mg/day after minimum 3 days 1
- Maximum dose: 100 mg/day 2, 1
- Extended maximum in some Asian guidelines: 120 mg/day 2, 3, 4
Geographic Variations in Maximum Dosing
The evidence shows regional differences in approved maximum doses:
- Japan: 120 mg/day (or 1.8 mg/kg) 2
- Malaysia: 100 mg/day 2
- India: 100 mg/day 2
- Republic of Korea: 1.4 mg/kg/day 2
Clinical studies have demonstrated safety and tolerability at 120 mg/day in Asian populations 3, 4, though FDA labeling typically caps dosing at 100 mg/day for adults 1.
Important Dosing Considerations
CYP2D6 Metabolizer Status
- Poor metabolizers (PMs): Achieve 10-fold higher plasma concentrations 1
- Consider lower maximum doses in PMs to avoid adverse effects
- Intermediate metabolizers (IMs): Show 1.4-2.2 fold higher concentrations than extensive metabolizers 5
Hepatic Impairment
- Moderate impairment (Child-Pugh Class B): Reduce to 50% of normal dose 1
- Severe impairment (Child-Pugh Class C): Reduce to 25% of normal dose 1
Renal Impairment
- No dose adjustment needed, even in end-stage renal disease 1
Common Pitfalls
Avoid rapid titration: Increasing dose too quickly leads to gastrointestinal symptoms and somnolence 6. The FDA label specifies waiting at least 3 days before increasing from 40 mg to 80 mg in adults 1.
Monitor for cardiovascular effects: Atomoxetine increases heart rate and blood pressure 6. Obtain cardiac history before initiating and monitor vital signs during treatment, particularly when approaching maximum doses.
Watch for suicidal ideation: FDA black box warning for increased suicidal thoughts, particularly during dose escalation 6.
Don't abruptly discontinue: Though less critical than with guanfacine/clonidine, gradual tapering is preferred 6.
Therapeutic Drug Monitoring
For children receiving once-daily morning dosing, peak plasma concentrations ≥268 ng/mL correlate with better response 5. CYP2D6 intermediate metabolizers may experience CNS and GI adverse effects at concentrations of 465-509 ng/mL 5.